# ANI Pharmaceuticals, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/ANI Pharmaceuticals, Inc). ## Overview ANI Pharmaceuticals is a U.S.-based biopharmaceutical company that develops, manufactures, and commercializes prescription therapeutics across Rare Disease, Generics, and Brands. Its portfolio includes specialty products such as Cortrophin Gel, ILUVIEN, and YUTIQ, alongside a broader generics business supported by its own manufacturing footprint in Minnesota and New Jersey. ## Products & services • Cortrophin Gel for rare disease indications • ILUVIEN ophthalmology implant for DME and NIU-PS • YUTIQ ophthalmology implant • Generic pharmaceutical products • Branded prescription pharmaceuticals • Royalties and other pharmaceutical services - **Rare Disease and Brands** (53%) — Includes Cortrophin Gel, ILUVIEN, YUTIQ, and other branded specialty products sold through limited-distribution channels. - **Generics** (44%) — Includes generic prescription pharmaceuticals sold primarily through wholesalers, retailers, and group purchasing organizations. - **Royalties and Other Pharmaceutical Services** (3%) — Includes royalty income and other service revenue tied to pharmaceutical commercialization and partnerships. - Cortrophin Gel rare disease therapy - ILUVIEN ophthalmology implant - YUTIQ ophthalmology implant - Generic pharmaceutical products - Branded prescription pharmaceuticals - Royalties and other pharmaceutical services ## Customers ANI sells mainly to pharmaceutical distribution intermediaries, specialty pharmacies, retail chains, and healthcare providers rather than directly to end patients. Its rare disease products depend on a narrower set of specialty pharmacies, hospitals, clinics, and physicians, while generics are sold through highly consolidated wholesaler and retail channels. Customer concentration is meaningful, with a small number of large customers representing a substantial share of revenue. - **Wholesalers and distributors** (primary) — Buy generic and branded products in bulk for downstream distribution; important because ANI relies on a concentrated U.S. channel structure. - **Specialty pharmacies** (primary) — Dispense rare disease products such as Cortrophin Gel to eligible patients and support limited-distribution commercialization. - **Retail pharmacy chains** (primary) — Purchase generic and branded medicines for broad consumer access through national pharmacy networks. - **Hospitals, clinics, and physicians** (secondary) — Buy and administer ILUVIEN and other specialty products in clinical settings, especially in ophthalmology. - **Payers and group purchasing organizations** (secondary) — Influence formulary access, rebates, and pricing terms that affect realized revenue and market penetration. - Large U.S. wholesalers buy generics and distribute into retail channels - Specialty pharmacies dispense Cortrophin Gel and other rare disease products - Retail pharmacy chains purchase branded and generic medicines - Hospitals, clinics, and physicians buy ILUVIEN for ophthalmology use - Payers and GPOs influence access, pricing, and reimbursement economics ## Geography ANI is headquartered and primarily operates in the United States, where most of its manufacturing, commercialization, and customer relationships are concentrated. The company also has international exposure through ILUVIEN, including direct marketing operations in Germany, the United Kingdom, Portugal, and Ireland, plus partnerships in Europe, Asia, and the Middle East. Geography matters because rare disease and ophthalmology products have broader non-U.S. reach than the generics business, while manufacturing and regulatory compliance remain anchored in the U.S. - U.S. is the core market for manufacturing and commercialization - Minnesota and New Jersey house the company's active manufacturing sites - ILUVIEN has direct marketing operations in parts of Europe - International partnerships extend reach into Asia and the Middle East - Former Oakville, Ontario site was sold and operations ceased ## Strategy ANI's strategy centers on expanding its rare disease and specialty franchise while maintaining a cash-generative generics base. The Alimera acquisition broadened its ophthalmology portfolio and international footprint, and the company continues to invest in commercialization, manufacturing capability, and selective acquisitions to deepen its product pipeline. - **Commercialize rare disease and ophthalmology products** (short-term) — Higher-value specialty products can improve growth and diversify away from commoditized generics pricing. - **Integrate and leverage the Alimera acquisition** (medium-term) — The acquisition adds products, international channels, and a stronger specialty platform. - **Expand manufacturing and supply resilience** (medium-term) — Owning manufacturing capacity supports product launches and reduces dependence on third parties. - **Use acquisitions to broaden the portfolio** (long-term) — ANI seeks additional products and assets to diversify revenue and support growth. - Scale Cortrophin Gel and ILUVIEN commercialization - Use Alimera to expand ophthalmology and international reach - Maintain generics as a base business and cash source - Invest in manufacturing capacity for new and acquired products - Pursue product and company acquisitions to broaden the pipeline ## Risks ANI faces concentration risk from a small number of large customers and channel partners, which can pressure pricing and volumes if relationships change. Its specialty products also depend on reimbursement, regulatory approvals, and successful commercialization, while generics remain exposed to intense price competition and supply-chain fragility. Debt, covenant compliance, and third-party manufacturing dependence add financial and operational risk. - **Customer concentration** [high] — A small number of wholesalers and distributors account for a large share of revenue, so lost business or renegotiated terms would materially affect sales. - **Generic pricing pressure** [high] — Generics compete mainly on price, contract terms, and service levels, which can compress margins and reduce volumes. - **Commercialization risk for Cortrophin Gel and ILUVIEN** [high] — Specialty products must gain and sustain market acceptance to offset generics volatility. - **Supply chain and single-source manufacturing dependence** [high] — Limited API suppliers and third-party manufacturers can cause delays, shortages, or compliance issues. - **Debt and covenant compliance** [medium] — Indebtedness and restrictive covenants can limit cash flow flexibility and trigger acceleration if breached. - **Regulatory and healthcare law compliance** [high] — Pharmaceutical operations are exposed to FDA, reimbursement, anti-kickback, and foreign regulatory regimes. - Revenue concentration leaves results sensitive to a few large customers - Generic pricing pressure can erode margins quickly - Specialty launches may underperform if market adoption is weak - API and single-source supplier dependence can disrupt production - Debt covenants and leverage can constrain flexibility ## Accounting ANI's reported revenue is heavily affected by estimates for chargebacks, rebates, returns, prompt-payment discounts, and government pricing programs, so gross-to-net deductions are a key analytical focus. The Alimera acquisition also introduces goodwill and intangible asset valuation risk, while revenue timing depends on transfer of control and can be affected by channel inventory and customer concentration. Because the company uses manufacturing facilities and third-party supply arrangements, provisions, restructuring, and asset impairment judgments can also move reported results. - **Revenue deductions and allowances** — Affects reported net sales and gross margin - **Revenue recognition timing** — Can shift revenue between quarters - **Goodwill and intangible assets** — Potential non-cash impairment charges - **Restructuring and asset disposal accounting** — Can distort year-over-year operating trends - **Inventory and manufacturing-related estimates** — Affects cost of goods sold and working capital - Gross-to-net deductions materially affect recognized net revenue - Revenue is recognized when control transfers to customers - Returns and chargebacks require significant estimation - Acquisition accounting adds goodwill and intangible asset impairment risk - Restructuring and asset-sale gains can affect comparability --- *Last updated: 2026-08-11T04:46:17.992183+00:00*